Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 31;15(7):1729.
doi: 10.3390/nu15071729.

Myokines: Crosstalk and Consequences on Liver Physiopathology

Affiliations
Review

Myokines: Crosstalk and Consequences on Liver Physiopathology

Aurore Dumond Bourie et al. Nutrients. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease mainly characterized by the hepatic accumulation of lipid inducing a deregulation of β-oxidation. Its advanced form is non-alcoholic steatohepatitis (NASH), which, in addition to lipid accumulation, induces hepatocellular damage, oxidative stress and fibrosis that can progress to cirrhosis and to its final stage: hepatocellular carcinoma (HCC). To date, no specific therapeutic treatment exists. The implications of organ crosstalk have been highlighted in many metabolic disorders, such as diabetes, metabolic-associated liver diseases and obesity. Skeletal muscle, in addition to its role as a reservoir and consumer of energy and carbohydrate metabolism, is involved in this inter-organs' communication through different secreted products: myokines, exosomes and enzymes, for example. Interestingly, resistance exercise has been shown to have a beneficial impact on different metabolic pathways, such as lipid oxidation in different organs through their secreted products. In this review, we will mainly focus on myokines and their effects on non-alcoholic fatty liver disease, and their complication: non-alcoholic steatohepatitis and HCC.

Keywords: HCC; NAFLD; NASH; diabetes; inter-organ crosstalk; metabolic disease; myokines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effects of myokines on glucose metabolism. This figure represents the beneficial and deleterious effects of different myokines on the different pathways involved in glucose metabolism: insulin sensitivity, glycogenesis, glycolysis, and gluconeogenesis. FGF21: Fibroblast growth factor 21; G6PC: Glucose-6-phosphatase catalytic subunit; GLUT2: Glucose transporter 2; IRS1/2: Insulin receptor substrate 1/2; LIF: Leukemia inhibitory factor; mTORC1: Mammalian target of rapamycin complex 1; PCK1: phosphoénol pyruvate carboxykinase; PGC1α: Peroxysome proliferator-activated receptor gamma co-activator 1-alpha.
Figure 2
Figure 2
Effects of myokines on lipid metabolism. This figure highlights the beneficial and deleterious effects of different myokines on the different pathways involved in lipid metabolism: fatty acid transport, de-novo lipogenesis, fatty acid β-oxidation and lipid droplet secretion. Acaca: acétyl-CoA carboxylase 1; BAIBA: β-aminoisobutyric acid; CD36: Cluster of differentiation 36; FABP: Fatty acid binding protein; FATP: Fatty acid transport protein; Fasn: Fatty acid synthase; IL-6: Interleukine 6; IL-15: Interleukine 15; LIF: Leukemia inhibitory factor; PPARα: Peroxisome proliferator-activated receptor alpha; SREBP: sterol regulatory element binding protein; STAT3: Signal transducer and activator of transcription 3.
Figure 3
Figure 3
Effects of myokines on NASH hallmarks. This figure represents the beneficial, but also the deleterious effects of different myokines on the different hallmarks of NASH: inflammation and fibrosis. HIF-1: Hypoxia inducible factor 1; IGFRIR: Insulin growth factor I receptor; IL-15: Interleukine 15; JNK-1: c-Jun N-terminal kinase 1; NK: Natural killer; α-SMA: Alpha-smooth muscle actin; TNF: Tumor necrosis factor.
Figure 4
Figure 4
Effects of myokines on hepatocellular carcinoma. This figure puts a light on the beneficial and deleterious effects of different myokines on the different pathways involved in the development of hepatocellular carcinoma: hepatic dysfunction, fibrosis, HCC cell invasion, migration and metastasis. gp130: Glycoprotein 130; HCC: Hepatocellular carcinoma; IL-6: Interleukine 6; IL-15: Interleukine 15; NK: Natural killer.

References

    1. Carr R.M., Oranu A., Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. Gastroenterol. Clin. N. Am. 2016;45:639–652. doi: 10.1016/j.gtc.2016.07.003. - DOI - PMC - PubMed
    1. Cotter T.G., Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158:1851–1864. doi: 10.1053/j.gastro.2020.01.052. - DOI - PubMed
    1. Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5:211–218. doi: 10.1136/flgastro-2013-100403. - DOI - PMC - PubMed
    1. Dallio M., Masarone M., Romeo M., Tuccillo C., Morisco F., Persico M., Loguercio C., Federico A. PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Front. Med. 2021;8:734847. doi: 10.3389/fmed.2021.734847. - DOI - PMC - PubMed
    1. Kitade H., Chen G., Ni Y., Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients. 2017;9:387. doi: 10.3390/nu9040387. - DOI - PMC - PubMed